Oncogene expression in cervical intraepithelial neoplasia and invasive cancer of cervix

• Published in: The Lancet (British edition) Vol. 337; no. 8745; pp. 819 - 820
• Main Authors: Pinion, S.B., Kennedy, J.H., Miller, R.W., MacLean, A.B.
• Format: Journal Article
• Language: English
• Published: London Elsevier Ltd 06.04.1991; Lancet; Elsevier Limited
• Subjects: Biological and medical sciences; c-Myc protein; Cancer; Carcinoma in Situ - genetics; Cervical cancer; Evaluation Studies as Topic; Female; Female genital diseases; GTP-binding protein; Gynecology. Andrology. Obstetrics; Health risk assessment; Histological Techniques; Human papillomavirus; Humans; Image analysis; Image processing; Invasiveness; Lesions; Medical research; Medical sciences; Myc protein; Oncogene Protein p21(ras) - analysis; Oncogene Protein p55(v-myc) - analysis; Oncogene Proteins v-erbA; Oncogenes; Proteins; Reproductive system; Retroviridae Proteins, Oncogenic - analysis; Tumors; Uterine Cervical Neoplasms - genetics; Cervical dysplasia; C-Onc gene; Tumor; Uterine cervix; Malignant tumor; Gene expression; Female genital diseases
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/0140-6736(91)92518-7

Expression of the oncogenes Ha-RAS, c-MYC, and ERB-2 was investigated with an automated image analysis system in 12 specimens of normal cervix, 10 of cervical intraepithelial neoplasia (CIN) grade 1,24 of CIN 3, and 10 of invasive cancer of the cervix. There was amplification of all three onocogenes in CIN 3 and invasive cancer compared with normal cervix and CIN 1. The difference was most pronounced with an antibody to the RAS p21 protein, with no overlap between CIN 3 and the normal range. This method might be useful in screening for cervical neoplasia, and for the determination of which CIN lesions require treatment.